OTCMKTS:GNMSF - Genmab A/S Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$437.27
▲ +17.24 (4.10%)
1 month | 3 months | 12 months
Get New Genmab A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNMSF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNMSF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $437.27.

Buy

The current consensus among 2 investment analysts is to buy stock in Genmab A/S.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/25/2020UBS GroupReiterated RatingBuy
i
8/13/2020BarclaysReiterated RatingOverweight
i
7/10/2020BarclaysReiterated RatingOverweight
i
10/1/2018HC WainwrightReiterated RatingBuy
i
Rating by R. Selvaraju at HC Wainwright
10/6/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
4/4/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
i
1/4/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
6/21/2016JPMorgan Chase & Co.Initiated CoverageNeutral
i
(Data available from 6/14/2016 forward)
Genmab A/S logo
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $437.27
$425.01
$437.35

50 Day Range

MA: $377.81
$324.50
$437.27

52 Week Range

Now: $437.27
$296.75
$456.83

Volume

200 shs

Average Volume

1,058 shs

Market Capitalization

$26.98 billion

P/E Ratio

6.20

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Genmab A/S?

The following Wall Street research analysts have issued research reports on Genmab A/S in the last year: Barclays PLC, and UBS Group AG.
View the latest analyst ratings for GNMSF.

What is the current price target for Genmab A/S?

0 Wall Street analysts have set twelve-month price targets for Genmab A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Genmab A/S in the next year.
View the latest price targets for GNMSF.

What is the current consensus analyst rating for Genmab A/S?

Genmab A/S currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GNMSF will outperform the market and that investors should add to their positions of Genmab A/S.
View the latest ratings for GNMSF.

What other companies compete with Genmab A/S?

How do I contact Genmab A/S's investor relations team?

Genmab A/S's physical mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The company's listed phone number is 45-7020-2728 and its investor relations email address is [email protected] The official website for Genmab A/S is www.genmab.com.